UPDATE: Peptides favored on 1st day of closely watched FDA compounding adcomm

An FDA advisory committee has recommended that three peptide drugs that were previously restricted because of potential safety concerns be restored to the 503A Bulk Drug Substances list, which woul | An FDA advisory committee has recommended that three peptide drugs that were previously restricted because of potential safety concerns be restored to the 503A Bulk Drug Substances list, which would remove the limits on how they are produced by compounders. It marks the first three of seven peptide drugs the FDA's Pharmacy Compounding Advisory Committee is addressing on Thursday and Friday.